GT Biopharma
GTBP
34 hedge funds and large institutions have $4.36M invested in GT Biopharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 15 closing their positions.
0.07% less ownership
Funds ownership: 0.34% → 0.27% (-0.07%)
28% less funds holding
Funds holding: 47 → 34 (-13)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
53% less capital invested
Capital invested by funds: $9.28M → $4.36M (-$4.92M)
87% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$83.4K |
| 2 |
VF
Virtu Financial
New York
|
+$63.4K |
| 3 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$51K |
| 4 |
Goldman Sachs
New York
|
+$36.6K |
| 5 |
State Street
Boston,
Massachusetts
|
+$22.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$333K |
| 2 |
E
Ergoteles
New York
|
-$242K |
| 3 |
Millennium Management
New York
|
-$230K |
| 4 |
Renaissance Technologies
New York
|
-$193K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$182K |
GTBP Hedge Fund Activity: Q3 2022 in Review
34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2022, worth a combined $4.36M — down 53% from $9.28M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of GTBP and 2 opened new positions — a net loss of 13 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Jane Street, opening a new position worth an estimated $83.4K. The largest seller was Morgan Stanley, cutting an estimated $333K.
- 34 institutional investors held GT Biopharma (GTBP) as of Q3 2022, down from 47 in Q2 2022.
- Funds reported $4.36M of GT Biopharma stock for Q3 2022, down 53% quarter-over-quarter.
- 2 funds opened new GT Biopharma positions in Q3 2022 and 15 closed out, a net change of -13 holders.
- The largest GT Biopharma buyer in Q3 2022 was Jane Street, an estimated $83.4K added.
- The largest GT Biopharma seller in Q3 2022 was Morgan Stanley, an estimated $333K sold.
Based on aggregated 13F filings for Q3 2022.